COMMUNIQUÉS West-GlobeNewswire

Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management
06/08/2026
Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants. SLIM-1 ™ trial is a Phase 1, randomized, controlled clinical trial design to characterize [...]
Clearmind Reaches Key Clinical Trial Milestone as DSMB Unanimously Clears Progression in AUD Study
06/08/2026
Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND‑100 in patients with Alcohol Use Disorder (AUD) - a key milestone in the [...]
vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
06/08/2026
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to [...]
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
06/08/2026
– On track for mid-2027 topline data readout from 80 patients in the Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast [...]
LENSAR® to Report Second Quarter 2026 Results on August 13th, 2026
06/08/2026
ORLANDO, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, [...]
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
06/08/2026
-- IND and CTA clearances in the United States and New Zealand establish a global Phase 1/2 program for PM577a in Wilson disease; study startup activities underway, with initial clinical data in 2027 -- -- Favorable [...]
Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments
06/08/2026
Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing Completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease; [...]
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1
06/08/2026
Obesity Treatment Candidate Designed to Preserve Lean Body Mass Toxicokinetic Findings De-Risk Dose Selection and Support Regulatory Pathway Toward IND MIAMI, Aug. 06, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc [...]
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
06/08/2026
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class [...]
Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update
06/08/2026
Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026 Concluded last patient last visit in CANYON-1 Phase 1b [...]
Actimed Therapeutics Reacquires Global Rights to S-oxprenolol, Broadening Pipeline Opportunity
06/08/2026
London, UK – 6 th August 2026. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting [...]
IBA Notice of Half Year 2026 Results and Conference Call
06/08/2026
HY26 results webcast to take place on Thursday, 27 August 2026 at 3 p.m. CEST Louvain-la-Neuve, Belgium, 6 August 2026, 7 a.m. - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator [...]
IBA : Publication des résultats du premier semestre 2026 et conférence web
06/08/2026
La conférence sur les résultats du premier semestre 2026 aura lieu le jeudi 27 août 2026 à 15h00, heure de Bruxelles Louvain-la-Neuve, Belgique, le 06 août 2026, 7h00 - IBA (Ion Beam Applications S.A le leader mondial [...]
Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update
06/08/2026
Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update Strategic partnering remains a key priority, with multiple strategic discussions progressing, including advanced term sheet [...]
Braveheart Bio Announces Pricing of Upsized Initial Public Offering
06/08/2026
SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other [...]
ARCPOINT ANNOUNCES FAILURE-TO-FILE CEASE TRADE ORDER
06/08/2026
GREENVILLE, South Carolina, Aug. 05, 2026 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “ Company ” or “ ARCpoint ”) announces that the British Columbia Securities Commission (the “ BCSC ”), as the Company’s [...]
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
06/08/2026
IRVINE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Thursday, August 6, 2026 to report its [...]
CellFiber and Tidewave Bio Enter Collaboration to Evaluate Scalable 3D Manufacturing for Next-Generation Solid Tumor Immunotherapy
06/08/2026
Partnership pairs CellFiber’s proprietary hollow-fiber encapsulation platform with Tidewave Bio’s universal, off-the-shelf cell immunotherapy program in a proof-of-concept process evaluation TOKYO and LOS ANGELES, Aug. [...]
UPDATE - LifeMD Reports Second Quarter 2026 Results
06/08/2026
UPDATE this press release has been updated to remove a duplicate table. Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of [...]

Pages